Methods of treating inflammatory pain

1. A method for treating arthritic pain and/or symptoms of arthritic pain in an individual, comprising peripheral administration to the individual of an effective amount of an anti-CGRP antagonist antibody.

2. The method according to claim 1 , wherein the anti-CGRP antagonist antibody is administered orally, sublingually, via inhalation, transdermally, subcutaneously, intravenously, intra-arterially, intra-articularly, peri-articularly, locally and/or intramuscularly.

3. The method according to claim 2 , wherein the anti-CGRP antagonist antibody is administered subcutaneously or intravenously.

4. The method according to claim 1 , wherein the anti-CGRP antagonist antibody acts peripherally on administration.

5. The method according to claim 1 , wherein the arthritic pain is osteoarthritis pain.

6. The method according to claim 1 , wherein the anti-CGRP antagonist antibody:

(a) binds to CGRP;

(b) blocks CGRP from binding to its receptor;

(c) blocks or decreases CGRP receptor activation;

(d) inhibits blocks, suppresses or reduces CGRP biological activity;

(e) increases clearance of CGRP; and/or

(g) inhibits CGRP synthesis, production or release.

7. The method according to claim 1 , wherein the anti-CGRP antagonist antibody:

(i) is a human antibody,

(ii) is a humanized antibody,

(iii) is a monoclonal antibody,

(iv) binds CGRP with a Kd of 50 nM or less (as measured by surface plasmon resonance at 37° C.); and/or

(v) has a half life in-vivo of at least 7 days.

8. The method according to claim 7 , wherein the anti-CGRP antagonist antibody specifically binds to amino acid residues 33-37 SEQ ID NO:15.

9. The method according to claim 1 , wherein the anti-CGRP antagonist antibody specifically binds to the C-terminal region of CGRP.

10. The method according to claim 1 , wherein the anti-CGRP antibody comprises:

(a) CDR H1 as set forth in SEQ ID NO: 3 or 21;

(b) CDR H2 as set forth in SEQ ID NO: 4 or SEQ ID NO: 22;

(c) CDR H3 as set forth in SEQ ID NO: 5 or 23;

(d) CDR L1 as set forth in SEQ ID NO: 6 or SEQ ID NO: 24;

(e) CDR L2 as set forth in SEQ ID NO: 7 or SEQ ID NO: 25;

(f) CDR L3 as set forth in SEQ ID NO: 8 or 26;

wherein the antibody binds CGRP with a Kd of 50 nM or less as measured by surface plasmon resonance at 37° C.

11. The method according to claim 1 , wherein the anti-CGRP antibody comprises a VH domain that comprises the amino acid sequence shown in SEQ ID NO: 1 and a VL domain that comprises the amino acid sequence shown in SEQ ID NO: 2.

12. The method according to claim 1 , wherein the anti-CGRP antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867.

13. The method according to claim 1 , wherein the anti-CGRP antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866.

14. The method according to claim 1 , wherein the anti-CGRP antibody is produced by the expression vectors with ATCC Accession Nos. PTA-6867 and PTA-6866.